agilon health, inc. (AGL)
| Market Cap | 904.76M -42.7% |
| Revenue (ttm) | 5.82B -2.8% |
| Net Income | -354.54M |
| EPS | -21.38 |
| Shares Out | 16.68M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 860,299 |
| Open | 61.39 |
| Previous Close | 60.66 |
| Day's Range | 51.61 - 61.39 |
| 52-Week Range | 7.48 - 85.00 |
| Beta | 2.30 |
| Analysts | Buy |
| Price Target | 47.61 (-12.21%) |
| Earnings Date | May 6, 2026 |
About AGL
agilon health, inc. provides healthcare services for seniors through primary care physicians in the communities of the United States. It offers a platform that manages the total healthcare needs of the patients by subscription-like per-member per-month. The company was formerly known as Agilon Health Topco, Inc. and changed its name to agilon health, inc. in March 2021. The company was founded in 2016 and is based in Westerville, Ohio.
Financial Performance
In 2025, agilon health's revenue was $5.93 billion, a decrease of -2.11% compared to the previous year's $6.06 billion. Losses were -$391.35 million, 50.4% more than in 2024.
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for AGL stock is "Buy." The 12-month stock price target is $47.61, which is a decrease of -12.21% from the latest price.
News
Agilon Health price target raised to $72 from $37.50 at Wells Fargo
Wells Fargo raised the firm’s price target on Agilon Health (AGL) to $72 from $37.50 and keeps an Overweight rating on the shares. The firm is encouraged by Q1 results
Agilon Health price target raised to $22 from $6.25 at BofA
BofA analyst Craig Jones raised the firm’s price target on Agilon Health (AGL) to $22 from $6.25 and keeps an Underperform rating on the shares. The firm revised estimates to
Agilon Health Is Up 115% After Earnings. Why the Stock Is Having Its Best Day Ever.
Shares of Agilon Health cratered in 2025, driven by financial underperformance and a guidance suspension.
Agilon Health price target raised to $35 from $20 at Baird
Baird raised the firm’s price target on Agilon Health (AGL) to $35 from $20 and keeps a Neutral rating on the shares. The firm updated its model following strong Q1
Agilon Health price target raised to $32 from $16 at Evercore ISI
Evercore ISI raised the firm’s price target on Agilon Health (AGL) to $32 from $16 and keeps an In Line rating on the shares.
Agilon Health upgraded to Buy from Hold at Deutsche Bank
Deutsche Bank upgraded Agilon Health (AGL) to Buy from Hold with a price target of $49, up from $33. The firm cites the improving macro environment and “compelling” share valuation
Agilon Health upgraded to Buy from Hold at Jefferies
Jefferies analyst Jack Slevin upgraded Agilon Health (AGL) to Buy from Hold with a price target of $48, up from $27.50. The company’s “strong” Q1 results and “clear signs” of
Agilon Health reports Q1 EPS $1.80, consensus 93c
Reports Q1 revenue $1.42B, consensus $1.38B. “Our strong first-quarter performance and increase in full-year 2026 guidance reflects disciplined execution and progress against our strategic priorities....
Agilon Health sees FY26 revenue $5.68B-$5.81B, consensus $5.45B
Sees FY26 total members 525K-540K.
agilon health Earnings Call Transcript: Q1 2026
First quarter results exceeded expectations, driven by operational improvements, enhanced data, and AI integration. Raised 2026 outlook with higher revenue and margin guidance, while maintaining a prudent cost trend assumption. Strong liquidity and new leadership position the company for continued growth.
agilon health Reports First Quarter 2026 Results
WESTERVILLE, Ohio--(BUSINESS WIRE)--agilon health, inc. (NYSE: AGL), the trusted partner empowering physicians to transform health care in our communities, today announced results for the first quarte...
Agilon Health downgraded to Underweight from Neutral at JPMorgan
JPMorgan downgraded Agilon Health (AGL) to Underweight from Neutral with an unchanged price target of $21. The firm believes it will take several quarters for investors to confidently underwrite a
Agilon Health names Tim O’Rourke as new CEO
agilon health (AGL) “announced the appointment of Tim O’Rourke as Chief Executive Officer and a member of the Company’s Board of Directors, effective May 7. He succeeds Ronald A. Williams,
agilon health Appoints Tim O'Rourke as Chief Executive Officer
WESTERVILLE, Ohio--(BUSINESS WIRE)--agilon health (NYSE: AGL) (the “Company”), the trusted partner empowering physicians to transform health care in our communities, today announced the appointment of...
Agilon Health price target raised to $17 from 60c at TD Cowen
TD Cowen raised the firm’s price target on Agilon Health (AGL) to $17 from 60c and keeps a Hold rating on the shares. The firm updated its model to reflect
Did agilon health, inc. Insiders Breach their Fiduciary Duties to Shareholders?
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible...
Agilon Health price target adjusted to $33 from $2 at Deutsche Bank
Deutsche Bank analyst George Hill adjusted the firm’s price target on Agilon Health (AGL) to $33 from $2 and keeps a Hold rating on the shares to reflect the reverse
Agilon Health price target adjusted to $16 at Evercore ISI after reverse split
Evercore ISI adjusted the firm’s price target on Agilon Health (AGL) to $16 from 75c and keeps an In Line rating on the shares after the company announced that it
agilon health Sets Date to Report First Quarter 2026 Financial Results
WESTERVILLE, Ohio--(BUSINESS WIRE)--agilon health, inc. (NYSE: AGL), the trusted partner empowering physicians to transform health care in our communities, today announced that it will release financi...
Agilon Health price target adjusted to $13 at Benchmark after reverse split
Benchmark adjusted the firm’s price target on Agilon Health (AGL) to $13 from $1.50 and keeps a Buy rating on the shares to reflect this week’s 1:25 reverse stock split
agilon health Announces Reverse Stock Split
WESTERVILLE, Ohio--(BUSINESS WIRE)--agilon health, inc. (NYSE: AGL) (the “Company”), the trusted partner empowering physicians to transform health care in our communities, today announced that it will...
agilon health Transcript: EGM 2026
Two proposals were presented: a reverse stock split amendment and a potential adjournment to solicit more proxies. Both proposals passed with Board support, and final vote results will be filed with the SEC.
agilon health Transcript: Barclays 28th Annual Global Healthcare Conference
A major transformation is underway, with new contracting and clinical pathway initiatives driving financial and operational improvements. Enhanced data and AI capabilities are improving disease identification and RAF score accuracy, while network management and disciplined contracting support stability and future growth.
agilon health Transcript: TD Cowen 46th Annual Health Care Conference
Cost trends remain elevated, especially in inpatient and oncology drug spend, but disciplined contracting and operational efficiencies have improved margins and cash position. Clinical programs and data enhancements support risk adjustment and member outcomes, while constructive payer relationships and portfolio refinement are expected to drive profitability in 2026 and beyond.
agilon health Earnings Call Transcript: Q4 2025
2025 saw foundational transformation, cost discipline, and strategic contract exits, resulting in improved data analytics and quality initiatives. 2026 guidance targets breakeven EBITDA, $5.5B revenue, and $300M–$350M medical margin, with continued focus on cost control and value-based care.